Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Identifieur interne : 003218 ( Main/Exploration ); précédent : 003217; suivant : 003219Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Auteurs : Charles J. Ryan [États-Unis] ; Matthew R. Smith [États-Unis] ; Karim Fizazi [France] ; Fred Saad [Canada] ; Peter F A. Mulders [Pays-Bas] ; Cora N. Sternberg [Italie] ; Kurt Miller [Allemagne] ; Christopher J. Logothetis [États-Unis] ; Neal D. Shore [États-Unis] ; Eric J. Small [États-Unis] ; Joan Carles [Espagne] ; Thomas W. Flaig [États-Unis] ; Mary-Ellen Taplin [États-Unis] ; Celestia S. Higano [États-Unis] ; Paul De Souza [Australie] ; Johann S. De Bono [Royaume-Uni] ; Thomas W. Griffin [États-Unis] ; Peter De Porre [Belgique] ; Margaret K. Yu [États-Unis] ; Youn C. Park [États-Unis] ; Jinhui Li [États-Unis] ; Thian Kheoh [États-Unis] ; Vahid Naini [États-Unis] ; Arturo Molina [États-Unis] ; Dana E. Rathkopf [États-Unis]Source :
- The Lancet. Oncology [ 1474-5488 ] ; 2015.
Descripteurs français
- KwdFr :
- Androstènes (usage thérapeutique), Antinéoplasiques hormonaux (usage thérapeutique), Humains, Mâle, Méthode en double aveugle, Prednisone (usage thérapeutique), Pronostic, Protocoles de polychimiothérapie antinéoplasique, Stade de la tumeur, Sujet âgé, Taux de survie, Tumeurs osseuses (mortalité), Tumeurs osseuses (secondaire), Tumeurs osseuses (traitement médicamenteux), Tumeurs prostatiques résistantes à la castration (anatomopathologie), Tumeurs prostatiques résistantes à la castration (mortalité), Tumeurs prostatiques résistantes à la castration (traitement médicamenteux), Études de suivi, Évolution de la maladie.
- MESH :
- anatomopathologie : Tumeurs prostatiques résistantes à la castration.
- mortalité : Tumeurs osseuses, Tumeurs prostatiques résistantes à la castration.
- secondaire : Tumeurs osseuses.
- traitement médicamenteux : Tumeurs osseuses, Tumeurs prostatiques résistantes à la castration.
- usage thérapeutique : Androstènes, Antinéoplasiques hormonaux, Prednisone.
- Humains, Mâle, Méthode en double aveugle, Pronostic, Protocoles de polychimiothérapie antinéoplasique, Stade de la tumeur, Sujet âgé, Taux de survie, Études de suivi, Évolution de la maladie.
English descriptors
- KwdEn :
- Aged, Androstenes (therapeutic use), Antineoplastic Agents, Hormonal (therapeutic use), Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms (drug therapy), Bone Neoplasms (mortality), Bone Neoplasms (secondary), Disease Progression, Double-Blind Method, Follow-Up Studies, Humans, Male, Neoplasm Staging, Prednisone (therapeutic use), Prognosis, Prostatic Neoplasms, Castration-Resistant (drug therapy), Prostatic Neoplasms, Castration-Resistant (mortality), Prostatic Neoplasms, Castration-Resistant (pathology), Survival Rate.
- MESH :
- chemical , therapeutic use : Androstenes, Antineoplastic Agents, Hormonal, Prednisone.
- drug therapy : Bone Neoplasms, Prostatic Neoplasms, Castration-Resistant.
- mortality : Bone Neoplasms, Prostatic Neoplasms, Castration-Resistant.
- pathology : Prostatic Neoplasms, Castration-Resistant.
- secondary : Bone Neoplasms.
- Aged, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Double-Blind Method, Follow-Up Studies, Humans, Male, Neoplasm Staging, Prognosis, Survival Rate.
Abstract
Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in men with chemotherapy-naive castration-resistant prostate cancer at the interim analyses of the COU-AA-302 trial. Here, we present the prespecified final analysis of the trial, assessing the effect of abiraterone acetate plus prednisone on overall survival, time to opiate use, and use of other subsequent therapies.
DOI: 10.1016/S1470-2045(14)71205-7
PubMed: 25601341
Affiliations:
- Allemagne, Australie, Belgique, Canada, Espagne, France, Italie, Pays-Bas, Royaume-Uni, États-Unis
- Berlin, Californie, Caroline du Sud, Catalogne, Colorado, Gueldre, Latium, Massachusetts, New Jersey, Texas, Washington (État), État de New York
- Barcelone, Berlin, Nimègue, Rome, Seattle
- Université de Washington
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003009
- to stream PubMed, to step Curation: 002F28
- to stream PubMed, to step Checkpoint: 002F28
- to stream Ncbi, to step Merge: 002179
- to stream Ncbi, to step Curation: 002179
- to stream Ncbi, to step Checkpoint: 002179
- to stream Main, to step Merge: 003219
- to stream Main, to step Curation: 003218
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.</title><author><name sortKey="Ryan, Charles J" sort="Ryan, Charles J" uniqKey="Ryan C" first="Charles J" last="Ryan">Charles J. Ryan</name><affiliation wicri:level="2"><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. Electronic address: ryanc@medicine.ucsf.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Smith, Matthew R" sort="Smith, Matthew R" uniqKey="Smith M" first="Matthew R" last="Smith">Matthew R. Smith</name><affiliation wicri:level="2"><nlm:affiliation>Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Harvard Medical School and Massachusetts General Hospital, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name><affiliation wicri:level="1"><nlm:affiliation>Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Gustave Roussy, University of Paris Sud, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Saad, Fred" sort="Saad, Fred" uniqKey="Saad F" first="Fred" last="Saad">Fred Saad</name><affiliation wicri:level="1"><nlm:affiliation>University of Montréal, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of Montréal, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Mulders, Peter F A" sort="Mulders, Peter F A" uniqKey="Mulders P" first="Peter F A" last="Mulders">Peter F A. Mulders</name><affiliation wicri:level="3"><nlm:affiliation>Radboud University Medical Centre, Nijmegen, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Radboud University Medical Centre, Nijmegen</wicri:regionArea><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author><author><name sortKey="Sternberg, Cora N" sort="Sternberg, Cora N" uniqKey="Sternberg C" first="Cora N" last="Sternberg">Cora N. Sternberg</name><affiliation wicri:level="3"><nlm:affiliation>San Camillo and Forlanini Hospitals, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>San Camillo and Forlanini Hospitals, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Miller, Kurt" sort="Miller, Kurt" uniqKey="Miller K" first="Kurt" last="Miller">Kurt Miller</name><affiliation wicri:level="3"><nlm:affiliation>Charité Berlin, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Charité Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Logothetis, Christopher J" sort="Logothetis, Christopher J" uniqKey="Logothetis C" first="Christopher J" last="Logothetis">Christopher J. Logothetis</name><affiliation wicri:level="2"><nlm:affiliation>MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Shore, Neal D" sort="Shore, Neal D" uniqKey="Shore N" first="Neal D" last="Shore">Neal D. Shore</name><affiliation wicri:level="2"><nlm:affiliation>Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC</wicri:regionArea><placeName><region type="state">Caroline du Sud</region></placeName></affiliation></author><author><name sortKey="Small, Eric J" sort="Small, Eric J" uniqKey="Small E" first="Eric J" last="Small">Eric J. Small</name><affiliation wicri:level="2"><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Carles, Joan" sort="Carles, Joan" uniqKey="Carles J" first="Joan" last="Carles">Joan Carles</name><affiliation wicri:level="3"><nlm:affiliation>Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Flaig, Thomas W" sort="Flaig, Thomas W" uniqKey="Flaig T" first="Thomas W" last="Flaig">Thomas W. Flaig</name><affiliation wicri:level="2"><nlm:affiliation>University of Colorado Cancer Center and University of Colorado School of Medicine, Aurora, CO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Colorado Cancer Center and University of Colorado School of Medicine, Aurora, CO</wicri:regionArea><placeName><region type="state">Colorado</region></placeName></affiliation></author><author><name sortKey="Taplin, Mary Ellen" sort="Taplin, Mary Ellen" uniqKey="Taplin M" first="Mary-Ellen" last="Taplin">Mary-Ellen Taplin</name><affiliation wicri:level="2"><nlm:affiliation>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Higano, Celestia S" sort="Higano, Celestia S" uniqKey="Higano C" first="Celestia S" last="Higano">Celestia S. Higano</name><affiliation wicri:level="4"><nlm:affiliation>University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="De Souza, Paul" sort="De Souza, Paul" uniqKey="De Souza P" first="Paul" last="De Souza">Paul De Souza</name><affiliation wicri:level="1"><nlm:affiliation>University of Western Sydney School of Medicine and Ingham Institute, Liverpool, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>University of Western Sydney School of Medicine and Ingham Institute, Liverpool</wicri:regionArea><wicri:noRegion>Liverpool</wicri:noRegion></affiliation></author><author><name sortKey="De Bono, Johann S" sort="De Bono, Johann S" uniqKey="De Bono J" first="Johann S" last="De Bono">Johann S. De Bono</name><affiliation wicri:level="1"><nlm:affiliation>The Institute of Cancer Research and the Royal Marsden Hospital, Sutton, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Institute of Cancer Research and the Royal Marsden Hospital, Sutton</wicri:regionArea><wicri:noRegion>Sutton</wicri:noRegion></affiliation></author><author><name sortKey="Griffin, Thomas W" sort="Griffin, Thomas W" uniqKey="Griffin T" first="Thomas W" last="Griffin">Thomas W. Griffin</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="De Porre, Peter" sort="De Porre, Peter" uniqKey="De Porre P" first="Peter" last="De Porre">Peter De Porre</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Research & Development, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Research & Development, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="Yu, Margaret K" sort="Yu, Margaret K" uniqKey="Yu M" first="Margaret K" last="Yu">Margaret K. Yu</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Park, Youn C" sort="Park, Youn C" uniqKey="Park Y" first="Youn C" last="Park">Youn C. Park</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development, Raritan, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, Raritan, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Li, Jinhui" sort="Li, Jinhui" uniqKey="Li J" first="Jinhui" last="Li">Jinhui Li</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development, Raritan, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, Raritan, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Kheoh, Thian" sort="Kheoh, Thian" uniqKey="Kheoh T" first="Thian" last="Kheoh">Thian Kheoh</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Naini, Vahid" sort="Naini, Vahid" uniqKey="Naini V" first="Vahid" last="Naini">Vahid Naini</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Molina, Arturo" sort="Molina, Arturo" uniqKey="Molina A" first="Arturo" last="Molina">Arturo Molina</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development, Menlo Park, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, Menlo Park, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Rathkopf, Dana E" sort="Rathkopf, Dana E" uniqKey="Rathkopf D" first="Dana E" last="Rathkopf">Dana E. Rathkopf</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25601341</idno><idno type="pmid">25601341</idno><idno type="doi">10.1016/S1470-2045(14)71205-7</idno><idno type="wicri:Area/PubMed/Corpus">003009</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003009</idno><idno type="wicri:Area/PubMed/Curation">002F28</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002F28</idno><idno type="wicri:Area/PubMed/Checkpoint">002F28</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002F28</idno><idno type="wicri:Area/Ncbi/Merge">002179</idno><idno type="wicri:Area/Ncbi/Curation">002179</idno><idno type="wicri:Area/Ncbi/Checkpoint">002179</idno><idno type="wicri:Area/Main/Merge">003219</idno><idno type="wicri:Area/Main/Curation">003218</idno><idno type="wicri:Area/Main/Exploration">003218</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.</title><author><name sortKey="Ryan, Charles J" sort="Ryan, Charles J" uniqKey="Ryan C" first="Charles J" last="Ryan">Charles J. Ryan</name><affiliation wicri:level="2"><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. Electronic address: ryanc@medicine.ucsf.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Smith, Matthew R" sort="Smith, Matthew R" uniqKey="Smith M" first="Matthew R" last="Smith">Matthew R. Smith</name><affiliation wicri:level="2"><nlm:affiliation>Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Harvard Medical School and Massachusetts General Hospital, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name><affiliation wicri:level="1"><nlm:affiliation>Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Gustave Roussy, University of Paris Sud, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Saad, Fred" sort="Saad, Fred" uniqKey="Saad F" first="Fred" last="Saad">Fred Saad</name><affiliation wicri:level="1"><nlm:affiliation>University of Montréal, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of Montréal, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Mulders, Peter F A" sort="Mulders, Peter F A" uniqKey="Mulders P" first="Peter F A" last="Mulders">Peter F A. Mulders</name><affiliation wicri:level="3"><nlm:affiliation>Radboud University Medical Centre, Nijmegen, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Radboud University Medical Centre, Nijmegen</wicri:regionArea><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author><author><name sortKey="Sternberg, Cora N" sort="Sternberg, Cora N" uniqKey="Sternberg C" first="Cora N" last="Sternberg">Cora N. Sternberg</name><affiliation wicri:level="3"><nlm:affiliation>San Camillo and Forlanini Hospitals, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>San Camillo and Forlanini Hospitals, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Miller, Kurt" sort="Miller, Kurt" uniqKey="Miller K" first="Kurt" last="Miller">Kurt Miller</name><affiliation wicri:level="3"><nlm:affiliation>Charité Berlin, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Charité Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Logothetis, Christopher J" sort="Logothetis, Christopher J" uniqKey="Logothetis C" first="Christopher J" last="Logothetis">Christopher J. Logothetis</name><affiliation wicri:level="2"><nlm:affiliation>MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Shore, Neal D" sort="Shore, Neal D" uniqKey="Shore N" first="Neal D" last="Shore">Neal D. Shore</name><affiliation wicri:level="2"><nlm:affiliation>Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC</wicri:regionArea><placeName><region type="state">Caroline du Sud</region></placeName></affiliation></author><author><name sortKey="Small, Eric J" sort="Small, Eric J" uniqKey="Small E" first="Eric J" last="Small">Eric J. Small</name><affiliation wicri:level="2"><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Carles, Joan" sort="Carles, Joan" uniqKey="Carles J" first="Joan" last="Carles">Joan Carles</name><affiliation wicri:level="3"><nlm:affiliation>Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Flaig, Thomas W" sort="Flaig, Thomas W" uniqKey="Flaig T" first="Thomas W" last="Flaig">Thomas W. Flaig</name><affiliation wicri:level="2"><nlm:affiliation>University of Colorado Cancer Center and University of Colorado School of Medicine, Aurora, CO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Colorado Cancer Center and University of Colorado School of Medicine, Aurora, CO</wicri:regionArea><placeName><region type="state">Colorado</region></placeName></affiliation></author><author><name sortKey="Taplin, Mary Ellen" sort="Taplin, Mary Ellen" uniqKey="Taplin M" first="Mary-Ellen" last="Taplin">Mary-Ellen Taplin</name><affiliation wicri:level="2"><nlm:affiliation>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Higano, Celestia S" sort="Higano, Celestia S" uniqKey="Higano C" first="Celestia S" last="Higano">Celestia S. Higano</name><affiliation wicri:level="4"><nlm:affiliation>University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="De Souza, Paul" sort="De Souza, Paul" uniqKey="De Souza P" first="Paul" last="De Souza">Paul De Souza</name><affiliation wicri:level="1"><nlm:affiliation>University of Western Sydney School of Medicine and Ingham Institute, Liverpool, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>University of Western Sydney School of Medicine and Ingham Institute, Liverpool</wicri:regionArea><wicri:noRegion>Liverpool</wicri:noRegion></affiliation></author><author><name sortKey="De Bono, Johann S" sort="De Bono, Johann S" uniqKey="De Bono J" first="Johann S" last="De Bono">Johann S. De Bono</name><affiliation wicri:level="1"><nlm:affiliation>The Institute of Cancer Research and the Royal Marsden Hospital, Sutton, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Institute of Cancer Research and the Royal Marsden Hospital, Sutton</wicri:regionArea><wicri:noRegion>Sutton</wicri:noRegion></affiliation></author><author><name sortKey="Griffin, Thomas W" sort="Griffin, Thomas W" uniqKey="Griffin T" first="Thomas W" last="Griffin">Thomas W. Griffin</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="De Porre, Peter" sort="De Porre, Peter" uniqKey="De Porre P" first="Peter" last="De Porre">Peter De Porre</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Research & Development, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Research & Development, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="Yu, Margaret K" sort="Yu, Margaret K" uniqKey="Yu M" first="Margaret K" last="Yu">Margaret K. Yu</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Park, Youn C" sort="Park, Youn C" uniqKey="Park Y" first="Youn C" last="Park">Youn C. Park</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development, Raritan, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, Raritan, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Li, Jinhui" sort="Li, Jinhui" uniqKey="Li J" first="Jinhui" last="Li">Jinhui Li</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development, Raritan, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, Raritan, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Kheoh, Thian" sort="Kheoh, Thian" uniqKey="Kheoh T" first="Thian" last="Kheoh">Thian Kheoh</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Naini, Vahid" sort="Naini, Vahid" uniqKey="Naini V" first="Vahid" last="Naini">Vahid Naini</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Molina, Arturo" sort="Molina, Arturo" uniqKey="Molina A" first="Arturo" last="Molina">Arturo Molina</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development, Menlo Park, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development, Menlo Park, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Rathkopf, Dana E" sort="Rathkopf, Dana E" uniqKey="Rathkopf D" first="Dana E" last="Rathkopf">Dana E. Rathkopf</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><series><title level="j">The Lancet. Oncology</title><idno type="eISSN">1474-5488</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Androstenes (therapeutic use)</term><term>Antineoplastic Agents, Hormonal (therapeutic use)</term><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Bone Neoplasms (drug therapy)</term><term>Bone Neoplasms (mortality)</term><term>Bone Neoplasms (secondary)</term><term>Disease Progression</term><term>Double-Blind Method</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Neoplasm Staging</term><term>Prednisone (therapeutic use)</term><term>Prognosis</term><term>Prostatic Neoplasms, Castration-Resistant (drug therapy)</term><term>Prostatic Neoplasms, Castration-Resistant (mortality)</term><term>Prostatic Neoplasms, Castration-Resistant (pathology)</term><term>Survival Rate</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Androstènes (usage thérapeutique)</term><term>Antinéoplasiques hormonaux (usage thérapeutique)</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Prednisone (usage thérapeutique)</term><term>Pronostic</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Taux de survie</term><term>Tumeurs osseuses (mortalité)</term><term>Tumeurs osseuses (secondaire)</term><term>Tumeurs osseuses (traitement médicamenteux)</term><term>Tumeurs prostatiques résistantes à la castration (anatomopathologie)</term><term>Tumeurs prostatiques résistantes à la castration (mortalité)</term><term>Tumeurs prostatiques résistantes à la castration (traitement médicamenteux)</term><term>Études de suivi</term><term>Évolution de la maladie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Androstenes</term><term>Antineoplastic Agents, Hormonal</term><term>Prednisone</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs prostatiques résistantes à la castration</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bone Neoplasms</term><term>Prostatic Neoplasms, Castration-Resistant</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Bone Neoplasms</term><term>Prostatic Neoplasms, Castration-Resistant</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Tumeurs osseuses</term><term>Tumeurs prostatiques résistantes à la castration</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Prostatic Neoplasms, Castration-Resistant</term></keywords><keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Tumeurs osseuses</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Bone Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs osseuses</term><term>Tumeurs prostatiques résistantes à la castration</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Androstènes</term><term>Antinéoplasiques hormonaux</term><term>Prednisone</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Disease Progression</term><term>Double-Blind Method</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Survival Rate</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Pronostic</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Taux de survie</term><term>Études de suivi</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in men with chemotherapy-naive castration-resistant prostate cancer at the interim analyses of the COU-AA-302 trial. Here, we present the prespecified final analysis of the trial, assessing the effect of abiraterone acetate plus prednisone on overall survival, time to opiate use, and use of other subsequent therapies.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Belgique</li><li>Canada</li><li>Espagne</li><li>France</li><li>Italie</li><li>Pays-Bas</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Berlin</li><li>Californie</li><li>Caroline du Sud</li><li>Catalogne</li><li>Colorado</li><li>Gueldre</li><li>Latium</li><li>Massachusetts</li><li>New Jersey</li><li>Texas</li><li>Washington (État)</li><li>État de New York</li></region><settlement><li>Barcelone</li><li>Berlin</li><li>Nimègue</li><li>Rome</li><li>Seattle</li></settlement><orgName><li>Université de Washington</li></orgName></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Ryan, Charles J" sort="Ryan, Charles J" uniqKey="Ryan C" first="Charles J" last="Ryan">Charles J. Ryan</name></region><name sortKey="Flaig, Thomas W" sort="Flaig, Thomas W" uniqKey="Flaig T" first="Thomas W" last="Flaig">Thomas W. Flaig</name><name sortKey="Griffin, Thomas W" sort="Griffin, Thomas W" uniqKey="Griffin T" first="Thomas W" last="Griffin">Thomas W. Griffin</name><name sortKey="Higano, Celestia S" sort="Higano, Celestia S" uniqKey="Higano C" first="Celestia S" last="Higano">Celestia S. Higano</name><name sortKey="Kheoh, Thian" sort="Kheoh, Thian" uniqKey="Kheoh T" first="Thian" last="Kheoh">Thian Kheoh</name><name sortKey="Li, Jinhui" sort="Li, Jinhui" uniqKey="Li J" first="Jinhui" last="Li">Jinhui Li</name><name sortKey="Logothetis, Christopher J" sort="Logothetis, Christopher J" uniqKey="Logothetis C" first="Christopher J" last="Logothetis">Christopher J. Logothetis</name><name sortKey="Molina, Arturo" sort="Molina, Arturo" uniqKey="Molina A" first="Arturo" last="Molina">Arturo Molina</name><name sortKey="Naini, Vahid" sort="Naini, Vahid" uniqKey="Naini V" first="Vahid" last="Naini">Vahid Naini</name><name sortKey="Park, Youn C" sort="Park, Youn C" uniqKey="Park Y" first="Youn C" last="Park">Youn C. Park</name><name sortKey="Rathkopf, Dana E" sort="Rathkopf, Dana E" uniqKey="Rathkopf D" first="Dana E" last="Rathkopf">Dana E. Rathkopf</name><name sortKey="Shore, Neal D" sort="Shore, Neal D" uniqKey="Shore N" first="Neal D" last="Shore">Neal D. Shore</name><name sortKey="Small, Eric J" sort="Small, Eric J" uniqKey="Small E" first="Eric J" last="Small">Eric J. Small</name><name sortKey="Smith, Matthew R" sort="Smith, Matthew R" uniqKey="Smith M" first="Matthew R" last="Smith">Matthew R. Smith</name><name sortKey="Taplin, Mary Ellen" sort="Taplin, Mary Ellen" uniqKey="Taplin M" first="Mary-Ellen" last="Taplin">Mary-Ellen Taplin</name><name sortKey="Yu, Margaret K" sort="Yu, Margaret K" uniqKey="Yu M" first="Margaret K" last="Yu">Margaret K. Yu</name></country><country name="France"><noRegion><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name></noRegion></country><country name="Canada"><noRegion><name sortKey="Saad, Fred" sort="Saad, Fred" uniqKey="Saad F" first="Fred" last="Saad">Fred Saad</name></noRegion></country><country name="Pays-Bas"><region name="Gueldre"><name sortKey="Mulders, Peter F A" sort="Mulders, Peter F A" uniqKey="Mulders P" first="Peter F A" last="Mulders">Peter F A. Mulders</name></region></country><country name="Italie"><region name="Latium"><name sortKey="Sternberg, Cora N" sort="Sternberg, Cora N" uniqKey="Sternberg C" first="Cora N" last="Sternberg">Cora N. Sternberg</name></region></country><country name="Allemagne"><region name="Berlin"><name sortKey="Miller, Kurt" sort="Miller, Kurt" uniqKey="Miller K" first="Kurt" last="Miller">Kurt Miller</name></region></country><country name="Espagne"><region name="Catalogne"><name sortKey="Carles, Joan" sort="Carles, Joan" uniqKey="Carles J" first="Joan" last="Carles">Joan Carles</name></region></country><country name="Australie"><noRegion><name sortKey="De Souza, Paul" sort="De Souza, Paul" uniqKey="De Souza P" first="Paul" last="De Souza">Paul De Souza</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="De Bono, Johann S" sort="De Bono, Johann S" uniqKey="De Bono J" first="Johann S" last="De Bono">Johann S. De Bono</name></noRegion></country><country name="Belgique"><noRegion><name sortKey="De Porre, Peter" sort="De Porre, Peter" uniqKey="De Porre P" first="Peter" last="De Porre">Peter De Porre</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003218 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003218 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25601341
|texte= Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25601341" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |